Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH )

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

59 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-14

Study Completion Date

2018-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to understand the early experiences of Feraccru® in patients with inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA) in the UK, including treatment effectiveness, patterns of use and tolerability.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

NCT02680756

Anemia, Iron-Deficiency Inflammatory Bowel Disease Crohn's Disease

COMPLETED PHASE3

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR

NCT00810030

Inflammatory Bowel Disease Anemia Iron Deficiency +3 more

COMPLETED PHASE3

Maintenance Treatment of Iron Deficiency in IBD Patients

NCT00810004

Iron Deficiency Inflammatory Bowel Disease

COMPLETED PHASE3

EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD

NCT06321887

Inflammatory Bowel Disease Iron Deficiency Anemia

RECRUITING PHASE3

Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial

NCT04587141

Iron Deficiency Anemia Inflammatory Bowel Diseases

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the study is to understand the early experiences of Feraccru® in patients with inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA) in the UK, including treatment effectiveness, patterns of use and tolerability. By describing the characteristics of patients treated with Feraccru® and their outcomes, this study will provide the medical community with important information to support treatment decisions for their patients. This will ultimately support improvements to patient care, including the long-term outcomes of patients with IBD and IDA

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia, Iron Deficiency Inflammatory Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients aged ≥ 18 years at the time of initiation .
* Patient presenting with mild to moderate IDA that is secondary to either Crohn's disease (CD) or ulcerative colitis (UC) defined as Hb ≥9.5 g/dL and \<13.0 g/dL in males, or Hb ≥9.5 g/dL and \<12.0 g/dL in females
* Serum ferritin concentration \<30 microgram/L or transferrin saturation of \<20% .
* Patient receiving Feraccru® since the time of UK launch in June 2016.

Exclusion Criteria

* Patient receiving Feraccru® as part of an interventional clinical trial.
* Patients with severely active IBD or requiring corticosteroids at the time of initiation on Feraccru®.
* Patient with an IBD flare, as determined by the clinician.
* Patient with medical records that are not available for review.
* Patient not willing or unable to consent to study participation, or patient is deceased at the start of data collection period

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No